Xiaobin Wu

Prof. Dr. Xiaobin Wu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2024 in Cancer Letters
Verified
Journal Article
Open access
NWNuoqing Weng
Nuoqing Weng
CZChuzhou Zhou
Chuzhou Zhou
YZYuhang Zhou
Yuhang Zhou
YZYanping Zhong
Yanping Zhong
ZJZhe Jia
Zhe Jia
XWXiaobin Wu
Xiaobin Wu
As an immune checkpoint protein expressed by diverse cancer cells, programmed death ligand 1 (PD-L1) facilitates immune evasion by interacting with programmed cell death-1 (PD-1) on T cells. Despite the clinical benefits observed in various cancer types, strategies targeting PD-1/PD-L1 have demonstrated limited efficacy in gastric cancer (GC). Furthermore, the regulation of PD-L1, especially at post-translational modification levels, remains largely unknown. Therefore, it is crucial to elucidate the mechanisms governing PD-L1 expression to enhance anti-tumor immunity. In this study, we have identified that IKAROS family zinc finger 4 (IKZF4) and Non-POU domain-containing octamer-binding (NONO) synergistically regulate and enhance the expression of RAB11 family-interacting protein 3 (RAB11FIP3) in GC. The IKZF4/NONO-RAB11FIP3 axis facilitates the endosomal recycling of PD-L1, particularly on the cell membrane of GC cells. Moreover, overexpression of RAB11FIP3 mitigates the hypo-expression of PD-L1 protein resulting from IKZF4 or NONO deletion. Functionally, the silencing of RAB11FIP3 or IKZF4 promotes T cell proliferation, and enhances T-cell cytotoxicity towards GC cells in vitro, which further inhibits tumor immune evasion in mice via increasing the infiltration of CD8+ T cells into the tumor microenvironment (TME) to suppress GC progression. Our study suggests that the IKZF4/NONO-RAB11FIP3 axis promotes immune evasion by facilitating PD-L1 endosome recycling, thus presenting a potential therapeutic target for GC treatment.

14 April 2025 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
WHWeizhen He
Weizhen He
HZHaoran Zhu
Haoran Zhu
XRXionghui Rao
Xionghui Rao
QYQinzhu Yang
Qinzhu Yang
HLHuixing Luo
Huixing Luo
YGYi Gao
Yi Gao

24 September 2023 in Thoracic Cancer
Verified
Journal Article
Open access
QYQinzhu Yang
Qinzhu Yang
HHHaofan Huang
Haofan Huang
GZGuizhi Zhang
Guizhi Zhang
NWNuoqing Weng
Nuoqing Weng
ZOZhenkai Ou
Zhenkai Ou
XWXiaobin Wu
Xiaobin Wu
Background: In view of the fact that radiomics features have been reported as predictors of immunotherapy to various cancers, this study aimed to develop a prediction model to determine the response to anti‐programmed death‐1 (anti‐PD‐1) therapy in esophageal squamous cell carcinoma (ESCC) patients from contrast‐enhanced CT (CECT) radiomics features.Methods: Radiomic analysis of images was performed retrospectively for image samples before and after anti‐PD‐1 treatment, and efficacy analysis was performed for the results of two different time node evaluations. A total of 68 image samples were included in this study. Quantitative radiomic features were extracted from the images, and the least absolute shrinkage and selection operator method was applied to select radiomic features. After obtaining selected features, three classification models were used to establish a radiomics model to predict the ESCC status and efficacy of therapy. A cross‐validation strategy utilizing three folds was employed to train and test the model. Performance evaluation of the model was done using the area under the curve (AUC) of receiver operating characteristic, sensitivity, specificity, and precision metric.Results: Wavelet and area of gray level change (log‐sigma) were the most significant radiomic features for predicting therapy efficacy. Fifteen radiomic features from the whole tumor and peritumoral regions were selected and comprised of the fusion radiomics score. A radiomics classification was developed with AUC of 0.82 and 0.884 in the before and after‐therapy cohorts, respectively.Conclusions: The combined model incorporating radiomic features and clinical CECT predictors helps to predict the response to anti‐PD‐1therapy in patients with ESCC.

1 February 2024 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
PDF file
PZPeng Zou
Peng Zou
CCChengru Chen
Chengru Chen
XWXiaobin Wu
Xiaobin Wu
Background: As one of the major metabolic reprogramming pathways, fatty acid oxidation (FAO) contributes to rapid progression in tumor cells. Nevertheless, the genomic patterns of patients’ FAO levels in colorectal cancer (CRC) remain unknown. Hence, it is crucial to identify the interplay mechanisms of molecular biochemical features of FAO in CRC. Methods: Data of patients with CRC were accessed from The Cancer Genome Atlas (TCGA). Unsupervised consensus clustering related to FAO sores was conducted. The differentially expressed genes (DEGs) were screened by clustering according to FAO status polarized in TCGA, followed by the construction of the scores of genes related to FAO (GFAO_Score). Enrichment of FAO and carcinogenesis at the cell level were calculated based on the single-cell RNA (scRNA) sequencing analysis. The clinical values and drug analysis of GFAO_Score were evaluated by external validation cohorts from Gene Expression Omnibus (GEO) datasets. Results: We classified patients into two distinct FAO clusters which indicated those with lower FAO levels had poor prognosis and high enrichment of carcinogenic-gene pathways. Further, the high FAO-enriched subtypes in epithelial cells revealed carcinogenesis. Three FAO-related genes (ZFHX4, AQP8, and AKR1B10) were screened to construct the GFAO_Score. The high GFAO_Score group leaned toward advanced CRC and unfavorable survival outcomes in the validation cohort. The low GFAO_Score group possessed a better response to immunotherapy and exhibited lower IC50 (50% inhibition concentration) values for certain chemotherapy drugs, such as 5-fluorouracil, irinotecan, oxaliplatin, paclitaxel, and camptothecin. Conclusions: FAO patterns vary in patients with CRC. The GFAO_Score might contribute to the precise screening of patients according to metabolism reprogramming and optimization of strategies in clinical practice.

23 September 2024 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
FXFu Xiao
Fu Xiao
YWYusong Wei
Yusong Wei
PZPeng Zou
Peng Zou
XWXiaobin Wu
Xiaobin Wu

23 August 2023 in Pathology - Research and Practice
Verified
Journal Article
Closed access
QHQiaoling Hu
Qiaoling Hu
YGYimin Guo
Yimin Guo
HFHuan Fan
Huan Fan
XWXiaobin Wu
Xiaobin Wu
HCHonglei Chen
Honglei Chen
CZChao Zeng
Chao Zeng